cabozantinib

Protein kinase inhibitors and activators - Cabozantinib is used in two forms. A capsule form is used since 2012 to treat medullary thyroid cancer and a tablet form is used since 2016 as a second line treatment for renal cell carcinoma.. Reference standards of Cabozantinib API, and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below

stdClass Object
(
    [pname] => Cabozantinib L-Malate
    [catalogue_number] => PA 30 62590
    [category_ids] => ,70,71,78,80,82,121,
    [chemical_name] => 
    [weight] => 635.59
    [form] => C32H30FN3O10
    [cas] => 1140909-48-3
    [pslug] => 1140909-48-3-cabozantinib-l-malate-api-standards-pa3062590
    [latest_product] => 0
    [linkproducts] => 1
    [offers_id] => 
    [offers_name] => 
    [offers_status] => 
    [offers_start_date] => 
    [offers_end_date] => 
    [pageview] => 
    [offers_slug] => 
    [offers_product_id] => 
    [offers_product_code] => 
    [offers_master_id] => 
    [offer_percentage] => 
    [offers_product_main_cat] => 
)
PA 30 62590
PA 30 62590

Cabozantinib L-Malate


  • Catalogue No.:PA 30 62590

  • CAS :

    1140909-48-3

  • Molecular Formula : C32H30FN3O10

  • Molecular Weight : 635.59

pharmaffiliates